Company profile
Telesis Bio, Inc.
OTC: TBIO · Healthcare · Medical - Devices
#320 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ 49GM —SS 29
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$13.5M
Rev growth YoY (TTM)
-54.9%
Net income (FY)
-$53.8M
Employees
39
as of 2026-08-24
Market cap
$78.4k
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$138.8M$138.8M2020
Net income-$53.8M-$53.8M2020
Operating income-$55.3M-$55.3M2020
Total assets$889.9M$889.9M2020
Liabilities$533.2M$533.2M2020
Equity$356.8M$356.8M2020
Revenue trend
FY2019 – FY2020 · USD
FY19
FY19
FY19
FY19
FY20
FY20
FY20
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Telesis Bio, Inc.’s revenue?
Telesis Bio, Inc. booked $138.8M in FY2020 revenue, growing 109% year over year — faster than most Healthcare companies we track, at a -38.7% net margin.
Peers · Healthcare
Beam Therapeutics Inc.62CSpok Holdings, Inc.83B+Quanterix Corporation56CNational Research Corporation75B+RxSight, Inc.59CXtant Medical Holdings, Inc.74BNeighbors
Middlesex →Key facts
CEOEric Esser
SectorHealthcare
IndustryMedical - Devices
HeadquartersLexington, MA
ExchangeOTC: TBIO
Employees39
IPO date2021-06-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.